Munich and Boston-based TVM Capital has invested an undisclosed sum in Riemser Arzneimittel AG. TVM Capital now holds 10% of the Riemser AG shares. TMV Capitals plans to help transition and grow Riemser Arzneimittel AG into an international corporation. Riemser Arzneimittel AG is a midsized pharmaceutical company on the island of Riems in Mecklenburg-Vorpommern, Germany. It has 450 employees at four manufacturing plants with annual revenues of about EUR 56m. The company develops and produces a line of successful dermatology, cardiovascular and anti-inflammatory, oncology and dental care pharmaceuticals.
Austria-based electrical engineering company had filed for insolvency in April 2020
VC house expects to hold a €35-45m first close by the end of July and a final close in around one year
LPs in Exponent III include Aberdeen Standard Investments, Central Pension Fund and CNP Assurances
Company has generated €12m in revenues and has a 25% EBITDA margin